β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)  by Bartus, Raymond T. et al.
Neurobiology of Disease 85 (2016) 11–24
Contents lists available at ScienceDirect
Neurobiology of Disease
j ourna l homepage: www.e lsev ie r .com/ locate /ynbd iReviewβ2-Adrenoceptor agonists as novel, safe and potentially effective
therapies for Amyotrophic lateral sclerosis (ALS)Raymond T. Bartus a,⁎, Alexandre Bétourné b, Anthony Basile c, Bethany L. Peterson b,
Jonathan Glass d, Nicholas M. Boulis e
a RTBioconsultants, Inc., San Diego, CA 92130, United States
b Above and Beyond, LLC, Atlanta, GA, United States
c Independent Consultant, Carlsbad, CA, United States
d Dept Neurology and Emory ALS Center, Emory University School of Medicine, Atlanta, GA, United States
e Dept Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States⁎ Corresponding author at: RTBioconsultants, Inc., 5442
E-mail address: bartus@RTBioconsultants.com (R.T. Ba
Available online on ScienceDirect (www.sciencedir
http://dx.doi.org/10.1016/j.nbd.2015.10.006
0969-9961/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 7 July 2015
Revised 25 September 2015
Accepted 8 October 2015
Available online 14 October 2015
Keywords:
β2-Adrenoceptor agonists
Repurposing drugs
ALS
Neuroprotection
Neurorestoration
Anabolic muscle effects
Neuromuscular junction
Motor neuron degeneration
Neuromuscular diseaseAmyotrophic lateral sclerosis (ALS) is a chronic and progressive neuromuscular disease for which no cure exists
and better treatment options are desperately needed. We hypothesize that currently approved β2-adrenoceptor
agonists may effectively treat the symptoms and possibly slow the progression of ALS. Although β2-agonists are
primarily used to treat asthma, pharmacologic data from animal models of neuromuscular diseases suggest that
these agentsmay have pharmacologic effects of beneﬁt in treating ALS. These include inhibiting protein degrada-
tion, stimulating protein synthesis, inducing neurotrophic factor synthesis and release, positively modulating
microglial and systemic immune function,maintaining the structural and functional integrity ofmotor endplates,
and improving energy metabolism. Moreover, stimulation of β2-adrenoceptors can activate a range of
downstream signaling events in many different cell types that could account for the diverse array of effects of
these agents. The evidence supporting the possible therapeutic beneﬁts ofβ2-agonists is brieﬂy reviewed, follow-
ed by a more detailed review of clinical trials testing the efﬁcacy of β-agonists in a variety of human neuromus-
cular maladies. The weight of evidence of the potential beneﬁts from treating these diseases supports the
hypothesis that β2-agonists may be efﬁcacious in ALS. Finally, ways to monitor and manage the side effects
that may arise with chronic administration of β2-agonists are evaluated. In sum, effective, safe and orally-
active β2-agonists may provide a novel and convenient means to reduce the symptoms of ALS and possibly
delay disease progression, affording a unique opportunity to repurpose these approved drugs for treating ALS,
and rapidly transforming the management of this serious, unmet medical need.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's
disease) is a chronic, progressive neuromuscular disease that primarily
involves a gradual loss of function and eventual death of motor neurons
in the spinal cord and brain, aswell as signiﬁcant atrophy of themuscles
they innervate. Clinically, ALS is characterized by stiff and/or twitching
muscles and signiﬁcant muscle weakness due to gradual muscle
wasting, resulting in difﬁculty ambulating, speaking, swallowing, and
eventually breathing. The average survival from diagnosis to death is
three to four years, though about 10% of ALS patients may survive
10 years ormore. There is no cure, with few treatment options currently
available. Riluzole reportedly can extend life expectancy about two to
three months and non-invasive ventilation may temporarily improve
quality and length of life. For all these reasons, efforts continue to try
to identify and develop more effective treatment options.
β-Adrenergic agonists share structural and pharmacological similar-
itieswith epinephrine.While these agents have been developed and ap-
proved primarily for the treatment of bronchial ailments such as asthma
and COPD (chronic obstructive pulmonary disease), accumulating
evidence demonstrates that their effects extend beyond smoothmuscle
relaxation and bronchodilation. Among the varied pharmacologic
effects of β-agonists, they may enhance skeletal muscle structure and
function, signiﬁcantly increasing muscle repair, bulk and strength by
stimulating protein synthesis and inhibiting protein degradation while
signiﬁcantly reducing body fat via the well-established ‘repartitioning
effect’ (Lynch and Ryall, 2008). While these effects were initially
exploited by the livestock industry, this use quickly expanded to include
human body builders and strength-training athletes. In more recent
years, experimental interest has further expanded to include clinical
tests of β-agonists in the treatment of a wide range of muscle-wasting
and neuromuscular diseases. These novel pharmacological effects, if
induced safely and reliably in humans, might signiﬁcantly improve the
status of ALS patients by reducing the magnitude of symptoms and
possibly slowing disease progression.This paper reviews data collected from various animal models of
muscle and neural degeneration that supports the use of β-agonists in
treating these pathologies, and examines the signaling pathways
induced by β2-agonists that may be responsible for these effects.
However, themajor focus is a detailed reviewof nearly three dozen clin-
ical publications reporting on the efﬁcacy of β-agonists in a number of
human neuromuscular disorders, including ALS. Collectively, these pa-
pers offer intriguing evidence supporting the hypothesis that β2-
agonists may be therapeutically valuable for treating ALS, as each of
the diseases share one or more important pathologies with ALS. The re-
view concludes with suggestions for monitoring and mitigating the po-
tential side effects that may occur following chronic β2-agonist
administration, to help assure that the hypothetical risks might be ac-
ceptable relative to the anticipated beneﬁts.
2. β2-Adrenoceptors: multiple signaling pathways produce diverse
pharmacologic beneﬁts
There are two groups of adrenergic receptors, α and β, each
composed of several subtypes (α1A,B,D, α2A,B,C; β1, β2 and β3). Within
skeletal muscles, α1-adrenoceptors are primarily located on the vascu-
lar smooth muscle of arterioles, where they control blood ﬂow through
the skeletal muscle (Lynch and Ryall, 2008), but otherwise do not affect
skeletal muscle function. In rodent skeletal muscles, β2 adrenoceptors
are the dominant subtype, accounting for 80–90% of the total
adrenoceptor content. The other isoform found in this tissue is the β1-
subtype, accounting for the remaining 10–20% of total adrenoceptor
content (Jensen et al., 1995; Kim et al., 1991). The β adrenoceptor
population in human skeletal muscles is almost exclusively comprised
of the β2-subtype (Liggett et al., 1988), although the presence of low
densities of β3-adrenoceptors has been suggested (Chamberlain et al.,
1999).
β2-Adrenoceptors are widely expressed on neurons throughout
the human central nervous system, particularly in the hippocampus,
and the prefrontal, parietal, temporal and motor cortices (Joyce et al.,
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ties of β2-adrenoceptors are found in the dorsal and ventral horns of
rat spinal cord (Atlas and Melamed, 1978; Mizukami, 2004; Patterson
and Hanley, 1987), with β-adrenoceptors homogeneously distributed
throughout the gray matter of the human spinal cord (Manaker et al.,
1988). While there have been few published studies characterizing
β-adrenoceptors on spinal cord motor neurons in the ventral horn (a
region critically degraded in ALS) β2-adrenoceptors do exist in many
brain regions whose degeneration has been shown to be important to
ALS (e.g., motor neocortex, frontal cortex, temporal cortex, hippocampus,
and cerebellum, among others) (Tsermentseli et al., 2012). This might be
especially important in view of ALS links to frontal-temporal dementia.
The extensive distribution of β2 adrenoceptors throughout the CNS is
consistent with their being ideal pharmacological targets for treating the
uppermotorandcognitivemanifestationsofALS. Inaddition to their location
on skeletal muscles, which suggests a role in maintaining peripheral
pathways essential for proper motor function, the presence of β2-
adrenoceptors on astrocytes, microglia and immunocytes in ventral horn
argues for a possible inter-cellular explanation for evidence that β2-
agonists can protect spinal cord neurons and restore/preserve their function.
Stimulation of β2-adrenoceptors activates many signaling pathways
linked to a variety of changes in different tissues and cell types (Fig. 1,
Table 1). This section provides an overview of the major β2-signaling
pathways that may be relevant to the treatment of ALS. More detailed
information may be found in other recent reviews (Joassard et al.,
2013; Lynch and Ryall, 2008).
2.1. β2-Adrenoceptor activation of the cAMP/PKA/CREB pathway
β2-Adrenoceptors belong to the G protein-coupled receptor family
and activate the canonical cAMP-dependent pathway. Following β2-
adrenoceptor stimulation, the receptor couples to the Gαs subunit and
activates adenylate cyclase, generating cAMP. This is a master signaling
pathway, with elevated cAMP levels driving multiple parallel signaling
pathways that play critical roles in regulating skeletal muscle, CNS and
immunocyte morphology and function (Fig. 1). A major effect of cAMP
is the activation of cAMP-dependent protein kinase A (PKA), which then
enters the cell nucleus and phosphorylates the ubiquitous transcription
factor CREB. CREB increases the expression of cAMP-inducible genes con-
taining the cAMP response element (CRE) sequence in mitochondria,
myocytes, neurons, astrocytes, microglia and immunocytes.
2.1.1. Enhancing protein metabolism
The hypertrophic effects of β2-agonists on skeletal muscle appear to
be mediated by activation of the cAMP/PKA/CREB pathway (Joassard
et al., 2013). Multiple β2-adrenoceptor induced signaling pathways stim-
ulate protein synthesis within cells, including CREB which regulates the
expression of numerous genes involved in skeletal myocyte differentia-
tion, the enhancement of protein synthesis and inhibition of protein
degradation (Joassard et al., 2013; Lynch and Ryall, 2008); see Fig. 1.
Moreover, neuronal β2-adrenoceptor activation of CREB has been
shown to promote the synthesis of proteins mandatory for neuronal ho-
meostasis (Gelinas and Nguyen, 2005; Zhou et al., 2013), and while not
yet empirically conﬁrmed in ALS, the presence of β2-adrenoceptors on
neurons throughout several brain regions affected by ALS raises the
possibility of neuroprotection and functional neurorestoration, as well.
2.1.2. Inhibiting proteolysis induced by the glutamate-calcium pathogenic
cascade
Glutamate toxicity is commonly recognized as an important patho-
genic event inALS, resulting in aberrantly high, toxic levels of intracellular
calcium. Calpains are a family of unique, non-lysosomal, Ca2+-dependent
proteases optimally active under neutral pH conditions. In response to
normal, regulated Ca2+-ﬂuxes, calpains initiate the controlled degrada-
tion of contractile proteins in skeletal muscle, and are implicated in
neuronal synapse formation, maintenance and remodeling. However,under conditions of calcium dysregulation, uncontrolled calpain-
mediated proteolysis has been implicated as an important pathogenic
player in the glutamate-calcium cascade in a number of diseases,
including ALS. Unregulated calpain activation has been shown to
cause signiﬁcant damage in many cell types, including muscle and
neurons due to uncontrolled proteolysis (Bartus, 1997). Consistent
with this idea, elevated calpain activity is observed in the brain and
spinal cord of ALS patients (Yamashita et al., 2012). β2-Agonists have
been shown to inhibit abnormal Ca2+-dependent calpain proteolysis
in muscle (Koopman et al., 2010; Lynch and Ryall, 2008), by increasing
the transcription of calpastatin, the endogenous inhibitor of calpain
activity, via CREB (Goncalves et al., 2012; Sensky et al., 2006), and/or
by the direct activation of constitutive calpastatin by PKA (Bartus,
1997; Lynch and Ryall, 2008; Navegantes et al., 2001). While these
effects of β-agonists have not yet been studied in neurons, the same
pathways exist in many CNS neurons expressing β2 receptors, and
may therefore produce the same beneﬁts.
2.1.3. Improving mitochondrial function
PGC-1α is a master regulator of mitochondrial biogenesis and
metabolism, and is enriched in skeletal muscle (Ruas et al., 2012).
β-Adrenergic signalingmay increase PGC-1α activity directly by stimu-
lation of PGC-1α (Chinsomboon et al., 2009; Peterson et al., 2013) or
indirectly through the activation of SIRT1 by PKA (Fig. 1) (Gerhart-
Hines et al., 2011). Regardless of the mechanism, acute stimulation of
β2-adrenoceptors rapidly increases PGC-1α levels in rodent skeletal
muscle (Koopman et al., 2010; Pearen et al., 2009). Moreover,
β2-agonists increase expression of mitochondrial genes targeted by
PGC-1α and inducemitochondrial biogenesis (Koopman et al., 2010). Re-
cently, alternative splice variants of PGC-1α have been identiﬁed (Ruas
et al., 2012), with the PGC-1α1 isoform associated with the promotion
of mitochondrial biogenesis, while PGC-1α4 induces muscle hypertrophy
independent of mitochondrial biogenesis (Ruas et al., 2012). Hence, β2-
agonists may activate PGC-1α1 driven mitochondrial biogenesis while
promoting the synthesis of other proteins by activating PGC-1α4.
2.1.4. Effects on neurotrophic factors in neurons
Stimulation of β2-adrenoceptors in neurons directly promotes the
synthesis and release of neurotrophic factors via the cAMP/PKA/CREB
pathway (Fig. 1). For example, β2-adrenergic stimulation activates
NGF and BDNF pro-survival pathways in rat neurons (Counts and
Mufson, 2010). IGF-1 is a neurotrophic factor that prevents decrements
in motor function and motor neuron loss while increasing survival in
the G93A-SOD1 mouse model of ALS (Kaspar et al., 2003). In muscles,
IGF-1 is induced by CREB induced elevations of a PGC-1α isoform
(Fig. 1). IGF-1 then promotes protein synthesis via autocrine activation
of the IGF-1 receptor and downstream PI3K-Akt signaling (Jesinkey
et al., 2014b; Rommel et al., 2001; Ruas et al., 2012). Hence, activation
of neuronal β2-adrenoceptors may provide neuroprotective beneﬁts to
ALS patients by increasing neurotrophic factors.
2.1.5. Effects on inﬂammation and trophic factor signaling in astrocytes
Astrocytes possess both β1- and β2-adrenoceptors (De Keyser et al.,
1999; Mantyh et al., 1995; Sutin and Shao, 1992), with the latter stimu-
lating the synthesis and release of neurotrophic and anti-inﬂammatory
factors in the CNS. The transcription factor NFκB is a major mediator of
astrocyte-mediated neuroinﬂammatory responses (Fig. 1) (Gavrilyuk
et al., 2002). Activation of the cAMP/PKA/CREB pathway decreases the
transcriptional activity of NFκB (Gerlo et al., 2011) and mediates the
clenbuterol induced suppression of NFκB inﬂammatory responses in
rat brain (Ryan et al., 2013). Astrocytic β2-receptor driven elevations
of cAMP also promote the synthesis and release of the trophic factors
BDNF, NGF, TGF-β1 and bFGF, producing anti-apoptotic and neuropro-
tective actions in rodent models of cerebral ischemia and excitotoxicity
(Culmsee et al., 2007; Culmsee et al., 1999; Day et al., 2014; Gleeson
et al., 2010; Riva et al., 1996).
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disease severity often correlatingwith the degree of astroglial activation.
There remains disagreement in the ALS ﬁeld as to whether activation of
astrocytes is a drivingpathogenic event, ormerely a response to ongoing
tissue destruction caused by unrelated factors. There is also data
suggesting that astrocytes derived from ALS patients are toxic to motor
neurons, and other evidence that a reduction in astrocyte-derivedtransporter molecules (EAAT) in ALS contributes to glutamate-
mediated toxicity. A number of studies using stem-cell derived astrocytic
implants have been conducted in non-clinical models of ALS and spinal
cord injury (Nicaise et al., 2015). The results of these studies are inconsis-
tent, offering at best temporary improvements in motor function. This
may reﬂect the complex nature of the astrocytic transplants and the
early stages of development of this therapeutic modality. Programs
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use in Phase I/II studies have recently been funded, and may yield valu-
able results in the future. Finally the so-called “Q trial”, administering
glia-derived precursor cells that theoretically are differentiated in vivo
to astrocytes is ongoing in an effort to protect motor neurons (https://
clinicaltrials.gov/ct2/show/NCT02478450?term=Q-therapeutics&rank=
1). Additionally, it is known that β2-adrenoceptor density is highly
elevated in reactive astrocytes derived from the spinal cords of ALS pa-
tients (De Keyser et al., 1999), and that stimulation of β2-adrenoceptors
confers selective neurotrophic and neuroprotective properties to astro-
cytes. Thus, agonist treatment of β2-adrenoceptors on endogenous
astrocytes may be effective in promoting motor neuron survival and
nerve regrowth in ALS patients.
2.1.6. Modulating microglia and immunocytes
Noradrenaline inﬂuences many immune cell functions, including
cytokine production, cell proliferation and antibody secretion (Elenkov
et al., 2000; Kin and Sanders, 2006). Most immunocytes express
β2-adrenoceptors, the activation of which triggers potent anti-
inﬂammatory and immunosuppressive effects (Carnevale et al., 2007).
Accordingly, β2-agonists are potent inhibitors of pro-inﬂammatory
cytokine release frommost immune cells (Theron et al., 2013), primarily
by the cAMP/PKA/CREB pathway, but also by an alternate cAMP-
dependent pathway (cAMP-Epac1/2-Rap1/2, Fig. 1). In particular,
β2-activation of the cAMP pathway inhibits proinﬂammatory cytokine
release by T-helper 1 (Th1) cells, while promoting the synthesis of
anti-inﬂammatory cytokines, favoring a protective Th2 response
(Carnevale et al., 2007). This effect may be of particular relevance in
ALS, where early, beneﬁcial immune responses shift to deleterious Th1-
driven immune responses with disease progression (Zhao et al., 2013).
Microglia are another immune cell type activated in ALS disease
and implicated as an important pathogenic event in motor neuron
degeneration (Turner et al., 2004; Zhao et al., 2013). Microglia express
high levels of β2-adrenoceptors and cAMP elevation following β2-
stimulation suppresses microglial proliferation and hypertrophy atten-
dant to inﬂammatory processes (Fujita et al., 1998; Tanaka et al.,
2002). β2-activation increases IκBα levels and downstream cAMP
signaling blocks microglial release of inﬂammatory cytokines and free
radicals (Colton and Chernyshev, 1996; Dello Russo et al., 2004;
Madrigal et al., 2005; Mori et al., 2002; Prinz et al., 2001). Consequently,
β2-supression of microglial activation reduces microglia-induced
neuronal cell death (Madrigal et al., 2006).
2.2. Non-cAMP/PKA/CREB pathways induced by β2-adrenoceptor
stimulation
Direct and indirect activation of the cAMP/PKA/CREB pathway by
β2-agonists results in an array of cellular responses. However, other
pathways directly activated by β2-agonists have potential in treating
ALS and deserve mention. β2-Adrenoceptors can switch coupling to
initiate alternate signaling events involving the PI3K–Akt–mTOR path-
way (Fig. 1) (Joassard et al., 2013). The ability of clenbuterol to attenuate
loss ofmusclemass in ratmodels ofmuscular atrophy has been linked to
activation of protein synthesis pathways involving mTOR (Kline et al.,
2007). Other alternate signaling pathways are illustrated in Fig. 1.Fig. 1. Summary of signaling pathways of particular relevance to ALS that aremodulated by acti
types involved in ALS, including skeletal muscle, glia, immunocytes and many neurons, with t
found). Nonetheless, as depicted in the ﬁgure, spinal cord motor neurons are directly impacted
stimulates a cascade of intracellular signaling pathways in these tissues, perhapsmost proliﬁc b
element binding protein (CREB) pathway. As depicted in the ﬁgure, a large and diverse array of
fector pathways. In addition to enhancing calpastatin, which inhibits aberrant calcium-depend
hancing protein synthesis, these pathways can inhibit nuclear factor kappa-light-chain-enhan
derived neurotrophic factor (BDNF) and nerve growth factor (NGF), peroxisome proliferator-
of these effectors can broadly enhance and/or protect the metabolic and functional perfor
immunocytes, and anti-inﬂammatory and potential neurotrophic effects through glia.2.3. Summary: β2-adrenoceptor modulated signaling pathways
It is difﬁcult to determine the relevance that an intracellular event
may have to a disease state outside the well-controlled conditions of
in vitro or ex vivo testing. The role of β2-adrenoceptor stimulation in
ALS is no exception. However, in a variety of cell types impacted by
ALS, β2-adrenoceptor activation modulates a number of intracellular
signaling pathways that maintain or enhance the viability of cells
under conditions of physical stress. The consistency of these effects
suggest that pharmacologically inducing these pathways using β2-
agonists could protect against the pathologic changes associated with
ALS and other neurodegenerative syndromes in intact animal models.
The following section reviews the literature supporting this hypothesis.3. Evidence for the neuroprotective effects of β-agonists in animal
models
Over 25 years of animal research has established that β-agonists
positively affect muscle function in vivo. β-agonists consistently
increase muscle strength and mass, reverse muscle wasting, and delay
the onset of motor deﬁcits in a wide range of animal models of muscle
degeneration (Joassard et al., 2013; Lynch and Ryall, 2008; Ryall and
Lynch, 2008). Similarly, the diverse signaling pathways induced by
β-agonists can protect neurons and promote neural repair following an
array of insults. While animal models absolutely predictive of therapeutic
efﬁcacy in ALS remain to be established (Rothstein, 2003), the pathways
induced by β-agonists might yield biologically-relevant improvements in
whole animals manifesting pathologies in common with ALS.
While a number of studies provide evidence of the neuroprotective
effects of β2-agonists, only two have been tested in putative models of
ALS. In the G93A-SOD1 mouse model of ALS (Teng et al., 2006), a single
dose level of the β-agonist clenbuterol produced a robust delay in the
onset of hind limb weakness as measured by performance on a rotarod
test. A modest, but statistically signiﬁcant slowing of disease progres-
sion as measured by Kaplan-Meier survival curves was also observed,
albeit solely in the female cohort, with a non-signiﬁcant trend toward
increased motor neuron survival. It remains uncertain whether more
robust responses may have been achieved if more than the single dose
level had been tested. A more recent report (Paik et al., 2015) tested the
non-selective β-agonist terbutaline sulfate in zebraﬁsh overexpressing
the mutant TDO-43 (Q331K), which develops motor axon degeneration
and defective neuromuscular junctions (NMJ). Treatment with terbuta-
line at 9h post-fertilization, before the onset of axonal outgrowth,
prevented the development of defects in axons and the NMJ. When
administered later post-fertilization, after motor neuron defects were
apparent, terbutaline effected a signiﬁcant rescue of motor axons and
NMJs. The authors predicted that terbutalinewas a promising candidate
for ALS based on their retrospective analysis of historic patient records
and drug–drug interactions using a mathematical model. These studies
support the concept that the signaling pathways induced by β-agonists
may produce biological changes that beneﬁt thewhole animal, andmay
be of therapeutic relevance to ALS.
Data fromother animalmodels of neurodegeneration provide greater
support for a role for β2-agonists protecting or repairing degenerating
motor neurons in ALS. Clenbuterol treatment delayed the developmentvation of β2-adrenoceptors. β2-Adrenoceptors are ubiquitously located onmany of the cell
he possible exception of spinal cord motor neurons (very few published results could be
by glia and immunocytes expressing β2 receptors. Agonist activation of β2-adrenoceptors
eing the cyclic adenosinemonophosphate (cAMP)/protein kinase A (PKA)/cAMP-response
pathways are activated, in turn inducing an even greater variety of secondmessenger/ef-
ent/calpain-mediated proteolysis (a key pathogenic event in glutamate toxicity) and en-
cer of activated B cells (NFκB), or activate effectors including neurotrophins such as brain
activated receptor gamma co-activator (PGC-1α), and inhibitor of NFκB alpha (IκBα). All
mance of skeletal muscle and neurons, as well as exert anti-inﬂammatory effects on
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mouse model, while reducing the proportion of motor neurons with
eccentric nuclei (a marker of synaptic dysfunction) (Zeman et al.,
2004). In addition, 6 weeks of clenbuterol signiﬁcantly reduced spinal
cord damage in a dose-related fashion following contusion injury in
rats (Zeman et al., 1999), while dose-dependent protection of the spinal
cord from ischemia and reperfusion injury was observed following clen-
buterol administration to rabbits (Chen et al., 2013). Other studies show
that β2-agonists protect neurons in vivo and in vitro by inhibiting
microglial activation (Qian et al., 2011), while suppressing the chronic-
relapsing pathology in the rodent EAE (experimental autoimmune
encephalomyelitis) model of multiple sclerosis (MS) by modulating
autoimmune pathologies (Wiegmann et al., 1995). Speciﬁcally, terbuta-
line reduced both the onset and recurrence of experimental MS by
inhibiting monocyte production, which plays a key role in pathogenesis
of MS. Terbutaline also suppressed experimental allergic neuritis in
Lewis rats by reducing demyelination and Wallerian degeneration,
while improving electrophysiological and functional motor endpoints
(Kim et al., 1994).
Further evidence of the neuroprotective properties of β2-agonists,
possibly mediated by the release of neurotrophic factors, was observed
using transgenic models of monogenetic neurodegenerative diseases.
The β2-agonist formoterol signiﬁcantly improved the synaptic density
and complexity of newly formed dentate granule neurons in the hippo-
campus, with signiﬁcant improvements in cognitive function in the
Ts65Dn mouse model of Down's syndrome (Dang et al., 2014). In the
Mecp2 nullmousemodel of Rett syndrome, characterized by neuromus-
cular dysfunction and degeneration, clenbuterol treatment improved
behavioral function and restored amicroRNA-mediated pathway down-
stream of BDNF, which affects normal IGF-1 expression (Mellios et al.,
2014). Several investigations have demonstrated that IGF-1 protects
degenerating spinal cord motor neurons in the SOD1-over express-
ing model of ALS (Franz et al., 2009; Kaspar et al., 2003; Lepore
et al., 2007). Using β2-agonists to increase IGF-1 levels (Fig. 1)
may have similar effects. Finally, β2-agonists such as formoterol
may induce mitochondrial biogenesis, restore the expression and
function of mitochondrial proteins and increase the copy number
of multiple genes involved in the mitochondrial electron transport
chain, presumably through activation of down-stream transcrip-
tion pathways (Jesinkey et al., 2014a; Wills et al., 2012). Given
the importance of mitochondria in neural function and repair,
and the role of mitochondrial dysfunction in the pathogenesis of
ALS (Cozzolino and Carri, 2012), this attribute could offer yet an-
other important pathway by which β2-agonists improve the status
of ALS.
3.1. Summary of the in vivo effects of β-agonists in animal models
β2-Adrenoceptor stimulation induces a range of positive effects in
animal models of neuromuscular degeneration. While none of these
models are predictive of therapeutic efﬁcacy in human diseases let
alone ALS, they indicate that the signaling pathways induced by β2-
agonists improve function and reduce or protect against tissue damage
in a number of organ systems. These changes could act synergistically
to suppress pathogenic elements of ALS, providing further evidence
that β2-agonists may reduce symptom severity and slow disease pro-
gression in ALS.
4. Clinical experience: tests of β-agonists in human neuromuscular
disorders
The clinical efﬁcacy of β2-agonists has been tested in a variety of
neuromuscular diseases. Currently, only a single, open label trial has
tested β2-agonists in ALS. Nonetheless, these nearly three dozen clinical
studies testing the therapeutic efﬁcacy ofβ-agonists in treating different
neuromuscular maladies may offer insights into their potential fortreating ALS. Despite their clear differences relative to ALS in etiology,
pathogenesis, pathology and certain symptoms, their commonalities
with ALS can be more important than their differences when deﬁning
opportunities for correcting ALS pathologies. For example, some of
these neuromuscular diseases have a primary neurologic pathology
(often including degeneration of motor neurons) that impacts themus-
culature innervated by the degenerating neurons, as in ALS (Table 1).
Other diseases are characterized by degeneration and dysfunction of
the NMJ (Table 2), negatively impacting both the host muscle and the
innervating motor neuron. Finally, the remaining disorders have a
primary myopathology that also impacts the NMJ and indirectly, the
innervating neuron (Table 3). By comparing and contrasting the ability
of β2-agonists to overcome these varying pathologies, one can gain
insight into the likelihood that similar disturbances in ALS might be
similarly improved.
4.1. Neuromuscular disorders with a primary neuropathology
The progressive neurodegeneration of upper and lower motor neu-
rons is generally recognized as the hallmark of ALS, with weakened,
atrophied muscles considered a secondary effect of axonal denervation.
Though the study and use β-agonists as anabolic agents for muscle has
a history longer and richer (Ryall and Lynch, 2008) than their possible
beneﬁt against neurodegeneration, a reasonable number of clinical tests
have nonetheless also been conducted in human diseases with a primary
neuronal genesis. These offer compelling, albeit preliminary support for
the hypothesis that β2-agonists may protect and/or restore function
andmorphology of degeneratingmotor neurons in ALS (Tables 1 and 2).
4.1.1. Amyotrophic lateral sclerosis
In the only study conducted testing a β2-agonist in ALS, clenbuterol
was administered at a single dose level to 16 subjects diagnosed with
progressive ALS (functional rating score ranging from 4–40) (Soraru
et al., 2006). In the 14 subjects completing this pilot study, the mean
composite myometer score for the upper limbs signiﬁcantly improved
from baseline by 20% at 3 months and 23% at 6 months (p = 0.01),
and for the lower limbs by 22% at 3 months and 27% at 6 months
(p = 0.0002). The mean composite MRC (Medical Research Center)
score of upper and lower limb strength trended toward improvement,
but was not statistically signiﬁcant. The mean forced vital capacity
(FVC) score trended toward improvement at 3 months (5%; p = 0.28)
and was signiﬁcant at 6 months (10%; p = 0.03). Despite these effects,
no change was observed in the ALS Functional Rating scale at either
assessment time point. Side effects were mild and always occurred
within the ﬁrst few days of starting dosing, quickly resolving without
altering dose. The most common complaints were hand tremors
(2 patients), cramps, fasciculations (3 patients), and nervousness
(3 patients). In no patient was heart rate increased or palpitations
observed. It should be noted that the mean dose of ~86 μg/kg/day is
well below the efﬁcacious doses of clenbuterol in preclinical models
(Ryall and Lynch, 2008). Therefore, while interpreting the results of
this pilot study is difﬁcult, it nonetheless supports the idea that further
effort to test higher doses in ALS iswarranted, possibly titrating doses to
limit the development of side effects, which based on other evidence,
may produce more robust and consistent effects than reported here.
4.1.2. Spinal bulbar muscular atrophy (SBMA)
SBMA is a debilitating neurodegenerative disorder of motor neurons
in the brain stem and spinal cord. It therefore shares with ALS an
important pathogenic neuronal deﬁcit as well as a clinical phenotype
of muscle cramps and progressive weakness.
A study in 20 SBMA patients (Querin et al., 2013) employed clenbu-
terol to induce both Akt and IGF-1, based on prior research in motor
neurons transduced to mimic SBMA showing that Akt and IGF-1
co-activation increased neuron survival (Palazzolo et al., 2007). In the
16 patients completing the study, a signiﬁcant and sustained increase
Table 1
Clinical trials in neuromuscular disorders with primary neuropathology.
DsX Paper Num. Drug Dose/day Length Design Efﬁcacy endpoints Notes
ALS Soraru et al. (2006) 16 (14) Clen 60 μg 6 mo Uncontrl Composite myometer
improved; MRC not improved
SBMA Querin et al. (2013) 20 (16) Clen 20 μg for 2 d;
then 40 μg/day
12 mo Uncontrl 6 min walk; fVC CK increase related both to
clen. & SBMA
SMA Kinali et al. (2002) 13 Albut 3 mg–8 mg 6 mo Uncontrl Myometry, fVC, MRC, lean
body mass
Dose was age-dependent
SMA Pane et al. (2008) 23 Albut 3 mg 1 wk.,
then 6 mg
12 mo Uncontrl Hammersmith scale improved
at 6 & 12 mo
SMA Tan (2011)) 2 Albut 6 mg 6 mo Uncontrl,
case rep
Neck & lung strength fVC
Mus atrophy/SC injur Signorile et al. (1995) 10 Meta-pro 80 mg 1 mo Blinded/
controlled
Muscle size & strength
Mus Atrophy/SC Injur Murphy et al. (1999)) 3 Albut 4 mg 2 wks/group Blinded/
X-over
Muscle mass muscle work
output
Denervated mus
atrophy
Jiang et al. (2011) 71 Clen 120 μg 3 mo Blinded/
controlled
Muscle atrophy improvement
MS Makhlouf et al. (2001) 16 Albut 4 mg: 1st wk.;
then 12 mg:
2nd wk
1 wk Uncontrl Reduced IL-12 producing
monocytes
MS Khoury et al. (2010) 44 Albut 4 mg 1 & 2 yrs Blinded/
controlled
Increased time to relapse;
improved MS functional comp.
at 6 mo & 1 yr. (primary
endpoint: 2 yrs)
Both active and placebo
received glatiramer
Deﬁnitions—ALS: amyotrophic lateral sclerosis, Alb: albuterol, blinded: double blind treatment, CK: creatine kinase, Clen: clenbuterol, controlled: randomized & placebo-controlled,
denervated musc atrophy: muscle atrophy after denervation, FVC: forced vital capacity, HMF Hammersmith motor functional scale, Meta: metaproterenol, MRC: manual muscle testing
with the Medical Research Council scale, MS: multiple sclerosis, musc atrophy/spinal cord inj: muscle atrophy after spinal cord injury, N: total subjects enrolled, (number of subjects
completing all protocol assessments); SBMA: spinal bulbar muscular atrophy; SMA: spinal muscular atrophy, uncontrl: uncontrolled; no placebo group; X-over: cross-over design (can
be blinded or not), but all patients alternatively receive both treatment and placebo. Note: for “Num” (i.e., number of subjects), the larger number refers to total subjects enrolled; number
in parenthesis refers to number of subjects that completed all protocol assessments (i.e., excludes subjects who withdrew from the protocol for any reason).
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capacity (p b 0.001). Side effects (primarily tremor and cramps) were
mild, transient and typically occurred early in the dosing schedule. In
two subjects the tremors caused early withdrawal. This open label
study, showing statistically signiﬁcant improvement of neuromuscular
performance in a serious motor neuron disease offers circumstantial
evidence supporting the hypothesis that oral β2-agonists may be
effective in ALS.4.1.3. Spinal muscular atrophy (SMA)
SMA is an autosomal recessive disease caused by a mutation in the
SMN1 gene, which encodes SMN, a protein necessary for motor neuron
survival. Four forms of SMA (types I-IV), distinguished by disease
severity, are commonly recognized. All share some semblance to the
degeneration and death of motor neurons characteristic of ALS.
Three small, open label clinical studies in patients with type II SMA
have been reported, all suggesting therapeutic beneﬁt. The ﬁrst treated
13 children with SMA II and III with albuterol (also called salbutamol,
especially in Europe) (Kinali et al., 2002). A signiﬁcant increase in
myometry scores, forced vital capacity and lean body mass was
observed (p b 0.05). Another open label trial testing albuterol in 23
young patients with SMA type II (Pane et al., 2008) observed a signiﬁ-
cant improvement in the Hammersmith motor functional scale at both
6 months and 1 year of treatment (p = 0.006). This was followed by
another open label study in two wheel-chair bound children with
SMA type II (Tan, 2011). Albuterol signiﬁcantly increased forced lung
capacity, and improved muscle strength so that they could, for the
ﬁrst time, perform several important daily activity tasks. Side effects
were not an issue in any of these studies. A potential mechanism for
albuterol's efﬁcacy in SMA patients was identiﬁed (Tiziano et al.,
2010). Albuterol was orally administered to 12 SMA type II-III subjects
and SMN2 full-length transcript levels were elevated in direct propor-
tion to the patients' SMN2 gene copy number. These data suggest that
albuterol (and likely other β-agonists), may act by elevating SMN2protein levels by a downstream signaling pathway stimulating SMN2
gene transcription or splicing. While SMN2 has not been implicated as
a pathogenic variable for ALS, it remains to be seen whether this mech-
anism of action may nonetheless beneﬁt ALS patients. That is, it might
be interesting to test whether elevating SMN2 to supraphysiological
levels could help improve the survival of degenerating motor neurons,
either in SOD1-over expressing mice or ALS patients, much as many
past investigators have argued for neurotrophic factors.
4.1.4. Muscle atrophy following spinal cord injury
Two double-blind, placebo controlled studies have administered
β-agonists to patients following serious spinal cord injuries. The
ﬁrst investigation was a small, randomized crossover design testing
metaproterenol versus placebo in paralyzed patients for four weeks
(Signorile et al., 1995). Objective measures of muscle strength and size
(expressed as cross-sectional area) were increased (p b 0.001). In the
second study, three patients with spinal cord injuries were given either
albuterol or placebo for twoweekswhile engaged in a functional electri-
cal stimulation (FES) cyclingprogram(Murphy et al., 1999). Increases in
mass of several muscles were seen, though contractile function of the
quadriceps muscle was not improved. Total work output signiﬁcantly
increased 64% with albuterol treatment compared to 27% with training
alone. Side effects weremild and transient. It is not clear howmuch this
improvement was due to muscle-only effects, versus a β2-agonist re-
covery of spinal cord neuron function (as seen in certain animal
studies).
4.1.5. Muscle atrophy following peripheral denervation
A randomized, double-blind, placebo-controlled study administering
either clenbuterol or placebo was performed on 71 patients suffering
from brachial plexus injuries (Jiang et al., 2011). As observed in animal
studies employing the same injury, clenbuterol ameliorated denervated
muscle atrophy in these patients. Since loss of muscle tone, bulk and
function occurs in ALS, due in part to denervation caused by the
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support for a possible beneﬁt of β2-agonists in ALS.
4.1.6. Multiple sclerosis (MS)
Multiple Sclerosis (MS) is the most common autoimmune disorder
causing chronic neurological disease. The autoimmune response
damages oligodendrocytes, causing axonal demyelination and functional
disability. Microscopically, the disease is characterized by perivascular
inﬁltrates of mononuclear cells. Some produce IL-12, which stimulates
T-cell proliferation as an important step in the pathogenesis of MS.
β2-Agonists are immunomodulators (Theron et al., 2013) and
decrease IL-12 expression by monocytes through the cAMP signaling
pathway (Panina-Bordignon et al., 1997). In one of two studies testing
β2-agonists in ALS, 16 progressive patients (aged 18–60 years) were
given daily albuterol (Makhlouf et al., 2001), which signiﬁcantly
reduced levels of IL-12-producing monocytes. Later, a double-blind
clinical trial tested whether albuterol improved clinical symptoms in
relapsing MS patients (Khoury et al., 2010). Forty-four subjects were
randomized to receive either albuterol-plus-glatiramer acetate (an
immunomodulator or ‘immune-decoy’ approved for MS) or placebo-
plus-glatiramer acetate. A delay to ﬁrst relapse (p = 0.03), as well as
an improvement in the Multiple Sclerosis Functional Composite
(MSFC) test was seen at 6 months (p = 0.005) and 12 months (p =
0.04) in the albuterol group. However, this improvement was lost by
24 months. Adverse effects were generally mild and dropout rates
between groups were equivalent. The authors concluded that albuterol
combined with glatiramer acetate improved MS over glatiramer alone.
While they did not comment on the loss of efﬁcacy by 24 months, it
seems plausible that it may have been due to β2-adrenoceptor desensi-
tization, which could have been prevented with either drug holidays or
increases in dose (see Section β-adrenoceptor desensitization). No
effort was made to monitor or control for this possibility.
4.2. Neuromuscular disorders characterized by the pathology of the
neuromuscular junction (NMJ)
Evidence strongly suggests that ALS progresses as an axonopathy,
wherein neurons degenerate in retrograde fashion from the NMJTable 2
Clinical trials in neuromuscular disorders characterized by a pathology of the NMJ.
DX Publication # subj Drug Total dose/day Length De
MG Liewluck et al. (2011) 3 + 15 Albut Adults: 4–12 mg
child: lower doses
1–25 mo Un
MG Burke et al. (2013) 9 Albut 3 m to 8 mg 1.5+ yrs Un
MG Gallenmuller et al. (2014) 2 Albut 8–12 mg NA Un
MG Lorenzoni et al. (2013) 5 Albut 6 mg 12 mo Un
MG Finlayson et al. (2013) 1 Albut 6 mg 12 mo Un
MG Soliven et al. (2009) 8 Terb 7.5 mg 2 wks each
leg
Bli
MG Mihaylova et al. (2008) 5 Ephe 2.2 to 3 mg/kg/day NA Ca
MG Bestue-Cardiel et al.
(2005)
2 Ephe 150–200 mg (doses
fractionated)
24 mo Un
MG Sadeh et al. (2011) 2 Albut 6 mg 6mo and 1 yr Un
MG Lashley et al. (2010) 12 (10) Ephe 15 to 90 mg/day 8 mo Un
MG Schara et al. (2009) 8 Ephe 25 mg then up to
75–100 mg
12 to 24 mo Un
Deﬁnitions — All subjects have major pathologies of the neuromuscular junction. ACh: acetylc
ephedrine, FVC: forced vital capacity, MG: myasthenia gravis, including congenital myastheni
subjects enrolled, (number of subjects completing all protocol assessments); QMG: Quantitat
X-over: cross-over design (can be blinded or not), but all patients alternatively receive both tre
total subjects enrolled; number in parenthesis refers to number of subjects that completed all prtoward the cell body in the spinal cord. Therefore, protecting the inter-
face of the motor neuron terminals and muscle ﬁbers seems prudent.
Moreover, because the pathogenesis of ALS may begin with the NMJ
(Dupuis and Loefﬂer, 2009), restoring and protecting NMJ integrity
and function may be necessary, although not sufﬁcient, for treating
ALS. The following section reviews a decade-long effort testing the
effects of β2-agonists in various myasthenic diseases, all characterized
by defects in the NMJ (Table 3). The beneﬁts reported offer further sup-
port for the hypothesis that β2-agonists might provide a novel therapy
for ALS.
Diseases characterized by the loss of transmission from motor
neurons to muscle and defects to the NMJ are grouped as myasthenia,
or myasthenia gravis (MG) for more severe forms. MG may be caused
by a congenital mutation or an acquired autoimmune component.
β-agonists have been tested in MG patients with mutations to DOK-7
(a muscle-speciﬁc protein essential for NMJ formation) and MuSK
(muscle speciﬁc kinase, responsible for signaling the motor neuron
terminal to dock with the motor endplate), as well as mutations or
deﬁciencies in acetylcholinesterase (AchE) or the acetylcholine receptor
in the endplate. Because the clinical designs of these studies vary mark-
edly, so does the strength of the data generated. Therefore, the results
are grouped on the following basis: (1) small case reports, (2) open-
label retrospective observations, (3) open-label prospective trials, and
(4) double-blind, controlled trials.
4.2.1. Small case studies
The ﬁrst publication testing a β-agonist in MG was a case involving
two severely impaired children (age 10 and 11) with a mutation-
mediated AChE deﬁciency who were given the non-speciﬁc α/β-
agonist, ephedrine in (Bestue-Cardiel et al., 2005). One subject was able
to climb a few steps but could only walk 200 mwithout rest; the second
could not lift her arms to a horizontal position, stand on one foot or walk
normally. Both patients responded “dramatically” to ephedrine, with
results persisting beyond 24 months. No serious adverse effects were
reported. Another case study (Sadeh et al., 2011) involved two congenital
myasthenic syndrome (CMS) patients with a mutation in the acetylcho-
line receptor who had a limited response to conventional therapies
(pyridostigmine; 3,4 diaminopyridine). Albuterol produced “a dramaticsign Efﬁcacy Other notes
contrl Walking distance & number of
steps climbed
Subjects had either DOK7
mutations or AChE deﬁciency
contrl Functional ability (walk. dis. &
reduced fatigue)
Escalating dosing schedule;
DOK7 mutations
contrl, Case Rep Walking and stair-climbing MUSK mutation
contrl QMG scores DOK7 mutations
contrl, case rep QMG score Slow channel myasth syndrome
nded; X-over QMG score (1° endpoint) &
neuromus trans. positive
Patients clinically Dx'd: MG no
change in FVC or grip strength
se rep Improved motor symptoms Patients all had COLQ mutations
contrl, case rep Mobility improved AChE deﬁciency
contrl, case rep Improved strength and in
activities-of-daily-living
Ach receptor mutation
contrl QMG, strength and mobility
scores improved
DOK7 mutation
contrl Muscle strength and exercise
tolerance; MRC scale
Dose escalation: start at
25; gradually increase to 75 to
100 mg; DOK7 mutation
holine, AChE: acetylcholinesterase; Alb: albuterol, blinded: double blind treatment, Eph:
c syndromes, MRC: manual muscle testing using Medical Research Council scale, N: total
ive myasthenia gravis score, Terb: terbuterol, uncontrl: uncontrolled; no placebo group,
atment and placebo Note: for “Num” (i.e., number of subjects), the larger number refers to
otocol assessments (i.e., excludes subjects whowithdrew from the protocol for any reason).
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adverse effects. In another single-patient case report (Finlayson et al.,
2013), a 62 year old CMS patient suffering motor impairments due to
acetylcholine receptor dysfunction was, following a second respiratory
arrest, given albuterol (along with the patient's normal ﬂuoxetine
which was regarded beforehand as only marginally effective, alone). A
year later, the Quantitative Myasthenia Gravis (QMG) score showed “a
striking reduction” (nearly 40%) in severity of symptoms. A ﬁnal case
report studied two brothers who had inherited a defect in MuSK
(Gallenmuller et al., 2014). At ages 13 and 16, both manifested serious
motor impairments. While esterase inhibitors were ineffective, within a
week of albuterol treatment a wheelchair bound patient was able to
climb stairs with a bannister while the other patient no longer required
any aids to walk, with further improvement occurring as the dose was
raised.
4.2.2. Open-label retrospective observations
In one of three retrospective trials, ephedrine was given to ﬁve
patients with mutations in the acetylcholinesterase (AChE) gene
(Mihaylova et al., 2008), and found to reduce motor deﬁcits more
effectively than AChE inhibitors and 3, 4-diaminopyridine. A second,
retrospective study (Liewluck et al., 2011) evaluated 15 patients with
DOK-7mutations and 3 patients with endplate AChE deﬁciency. Albute-
rol produced signiﬁcant improvements in a 9-point activities-of-daily-
life questionnaire in both diagnostic groups (p b 0.001). One patient ex-
perienced atrial ﬂutter at 2 weeks, causing treatment to be stopped. All
other side effects, including muscle cramps, jitteriness, tremor, insom-
nia and hypertension, were reported to be mild, tolerable, transient,
and expected. A ﬁnal retrospective study (Burke et al., 2013) reported
that albuterol produced progressive improvement in all nine children
(6 to 15 years old) treated within one month of dosing; the 3 non-
ambulatory patients all resumed walking with assistance.
Improvements were seen in a number of timed tests as well as a
functional test-of-daily-living, with a plateau in improvement reached
within one to 1.5 years. No major side effects were reported.
4.2.3. Open-label prospective trials
Four prospective clinical trials were conducted testing β-agonists
against myasthenia, one of which was controlled. The ﬁrst was an
open-label, dose-escalation paradigm testing ephedrine in 8 patients
with DOK mutations (Schara et al., 2009). Dose-escalation continued
until either improvement or side effects were observed. Within weeks,
clinical assessments and reports from patients and families established
improved muscle strength and exercise tolerance in all patients,
particularly in their proximal muscles. No improvement was seen in
FVC or neurophysiological tests involving repetitive stimulation. The
drug was well tolerated. Another prospective study in 12 patients
with a DOK-7 mutation showed progressive improvement in the QMG
score (p = −0.009) and mobility scores (p = 0.0006) over the 6 to
8 month assessment period (Lashley et al., 2010). Proximal muscles
were most robustly improved, as were activities of daily living. Ten of
the 12patients tolerated ephedrine (15 to 90mg/day); 1 had intolerable
insomnia and the other elevated blood pressure, but apparently no
effort was made to temporarily lower the dose until tolerance to these
side effects might occur (see section on controlling side effects). The
third, open-label prospective study tested albuterol in 5 patients with
a DOK-7 mutation (Lorenzoni et al., 2013). QMG scores at 3, 6, 9 and
12months showed a “clear beneﬁcial response”. Albuterolwas generally
well tolerated, though some mild side effects (e.g., tremor, occasional
palpitations and headache) were initially seen but soon dissipated.
Finally, a most-noteworthy, randomized, double-blind, placebo-
controlled cross-over study in 8 subjects with generalized MG tested
the selective β-agonist terbutaline (Soliven et al., 2009). Despite the
small sample size (and lack of statistical power), the QMG score (the
predesignated primary endpoint) showed a signiﬁcant improvement
over placebo (p = 0.03), as did neuromuscular transmission, based onrepetitive nerve stimulation (p b 0.05). On theother hand, the functional
disability scale, grip measurements and FVC did not show statistically
signiﬁcant improvement. Terbutaline was well tolerated in all study
subjects.
4.2.4. Summary of β-agonist trials in myasthenia gravis
Eleven separate clinical studies have been published by eleven
independent groups of investigators administering β-agonists to
patients with MG of varying etiologies and pathologies (Table 2).
Despite these differences, their single commonquality is that stimulating
β2-adrenoceptors may provide important symptomatic relief. While
only a few of the studies offer conclusive or convincing evidence of
efﬁcacy (particularly the uncontrolled trials), collectively they provide
intriguing evidence that β-agonists may have some efﬁcacy in treating
MG. Though a clear mechanism of action has yet to be elucidated, the
fact that such varied etiologies of MG show evidence of possible clinical
beneﬁt offers support for the hypothesis that β-agonists might well
beneﬁt other diseases where degeneration and dysfunction of the NMJ
is an important component of their pathogenesis, such as ALS. The ability
of β-agonists to provide apparent beneﬁt to MG, despite the pathogenic
diversity of NMJ degeneration provides support for the hypothesis that
they may also provide beneﬁt for whatever pathogenic variable(s) are
most responsible for the NMJ degeneration in ALS.
4.3. Neuromuscular disorders with a primary myopathology
These disorders differ fundamentally from ALS in that their major
pathologies are driven by muscle abnormalities. Nonetheless, evidence
that β-agonists may improve their symptoms suggests a possible
beneﬁt for ALS, given that gradual loss of muscle strength and function
is an important part of the ALS phenotype. Therefore, the efﬁcacy of
β-agonists in treating diseases that primarily involve degeneration of
the musculature suggests utility in treating ALS. However, because it
does not directly address the main deﬁciencies of ALS, a review of the
individual studies will be more cursory, complemented by individual
listings in Table 3.
4.3.1. Muscular dystrophy (MD)
Muscular dystrophy refers to a group of muscle diseases that share
the important clinical phenotype of a weak and progressively deterio-
rating musculoskeletal system, caused by defects in muscle proteins
and degeneration and death of muscle cells, clinically accompanied by
signiﬁcant impairments in locomotion. Duchenne is the most common
childhood form of muscular dystrophy and is caused by mutations or
deletions in the DMD-gene, which expresses dystrophin (a cytoplasmic
protein essential for the integrity of the muscle cell).
Three small, open label trials were conducted with albuterol. In two
of the three (Fowler et al., 2004; Skura et al., 2008), a signiﬁcant increase
in lean bodymass and reduced fatmasswas achieved, though no differ-
ences were found in isometric knee, manual muscle tests, or time to
run/walk 30 ft. Importantly, in another small study of four different
types of muscular dystrophy, clenbuterol was beneﬁcial to muscles
whose mass was more preserved, but failed to improve the most
atrophic muscles. This suggests that β-agonists may be most effective
in the early stages of muscular dystrophies and atrophies.
4.3.2. Facioscapulohumeral dystrophy (FSHD)
FSHD is an autosomal dominant disease caused by a dual genetic
error involving a ‘toxic gain of function’ of the DUX4 gene (a
homeodomain transcription factor), along with deletion of D4Z4
repeats. It usually affects the skeletal muscles of the face, scapula and
upper arms.
Four clinical trials tested albuterol in FSHD, three of which were
randomized, double-blind controlled designs (Kissel et al., 2001;
Payan et al., 2009; van der Kooi et al., 2004). Collectively, the results of
these tests of albuterol in FSHD are mixed, in that 3 of the 4 studies
Table 3
Clinical trials in neuromuscular disorders with a primary myopathology.
DX Publication # subj Drug Total dose/day Length Design Efﬁcacy Other notes
DMD Fowler et al. (2004) 9 Albut 4 mg for 4 d then 8 mg 12 wks Blinded;
X-over
Isometric knee extensor and
MMT improved
DMD Skura et al. (2008) 14 Albut 12 Mg: Sustained release 3 mo
each arm
Blinded;
X-over
Time to walk 30 m and lean
body mass improved
Isometric knee and MMT
showed no effect
MD mixed Oya et al. (2001) 4 Clen 30 and 40 μg 6–18 mo Uncontrl Muscles mass increased Beneﬁts only early in disease
FSHD Kissel et al. (1998) 15 Albut 8 mg: 1 wk. then 16 mg 3 mo Uncontrl Lean body mass increased and
MVICT improved
FSHD Kissel et al. (2001) 90 (84) Albut 8 mg to 32 mg (dose
escalation/wk: 8 mg;
16 mg; 16 mg–32 mg)
13 mo Blinded/
controlled
Muscle mass and strength
improved
MVICT and MMT showed no
effect
FSHD van der Kooi et al. (2004) 65 (61) Albut 8 mg for 2 wks then
16 mg
6.5 mo Blinded/
controlled
Muscle volume increased and
MVICT improved
FSHD Payan et al. (2009) 56 Albut 16 mg: Sustained release 6 mo Blinded/
controlled
No sig. Beneﬁt on QMT, MMT
or timed motor tasks
Dosing schedule: 3 wks on;
1 wk. off
Post-surgery Maltin et al. (1993) 20 Clen 40 μg 1 mo Blinded/
Controlled
Leg strength improved
Cachx Greig et al. (2014) 13 (7) Form 80 μg 2 mo Uncontrl Muscle size/function increased;
quad &grip strength improved
Also given appetite stimulant
(megestrol)
AMD Angelini et al. (2004) 5 Albut 6 to 12 mg/day IV for
10 days; then monthly
6 mo Uncontrl Improved muscle mass and
global functional tests
Long-term follow up for over
3 years
CCD Schreuder et al. (2010) 1 Albut 8 mg 1 yr Uncontrl,
case rep
Improved FEV; increased
strength
Central core disease, plus
mitochondrial dysfunction
CCD Messina et al. (2004) 13 (10) Albut 8 mg 6 mo Uncontrl Improved myometry; MRC
scores, FVC
Deﬁnitions — Alb: albuterol, AMD: acid maltase deﬁciency, CCD: central core disease, Clen: clenbuterol, controlled: randomized & placebo-controlled, DMD: Duchenne's and Becker's
muscular dystrophy, FSHD: facioscapulohumeral dystrophy, Form: formoterol;MD:muscular dystrophy, FEV: forced expiratory capacity, FVC: forced vital capacity, MMT: manual muscle
test,MRC:Medical Research Council,MVICT:maximumvoluntary isometric contraction,N: total subjects enrolled (number of subjects completing all protocol assessments); post-surgery:
post surgical muscle recovery, QMT: quantitative muscle testing, uncont: uncontrolled; no placebo group, X-over: cross-over design (can be blinded or not), but all patients alternatively
receive both treatment and placebo.
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randomized, double-blind, placebo-controlled trials was able to achieve
statistical signiﬁcance on its a priori-deﬁned, primary outcomemeasure
(van der Kooi et al., 2004). These results are therefore intriguing, but
must be considered inconclusive. Uncertainty remains as to whether
more robust and consistent effectsmight be achievedwithmore potent,
long-lasting and selective β2-agonists (e.g., clenbuterol, formoterol), as
well as the use of a dosing schedule designed to minimize transient
side effects and β2-adrenoceptor desensitization.
4.3.3. Acid maltase deﬁciency (AMD)
Acid maltase deﬁciency (also called Pompe disease and Glycogen
Storage Disease type II) is a lysosomal storage disease resulting from a
genetic defect that causes a lack of acid maltase, which normally breaks
down glycogen. This causesmuscularwasting, accompanied by a slowly
progressing weakness. Like ALS, respiratory complications are the main
cause of death.
An open-label, prospective study (Angelini et al., 2004) tested
intravenous albuterol in 5 adult AMD patients. A late-stage elderly
patient who had been diagnosed 40 years earlier required an overnight
respirator and had the worst functional score. He could not tolerate i.v.
albuterol and was not included in the analysis. The other four subjects
showed varying improvements in the functional scale score and the
MRC Score (Medical Research Council) composite.
4.3.4. Central core disease (CCD) and multi-mini core disease
Central core disease is an autosomal dominant congenital myopathy
disease caused by mutations in the gene that expresses the ryanodine
receptor 1 (essential for skeletal muscle function), while multi-minicore
disease shares somewhat similar clinical and pathologic features. Both
are manifested by a loss in muscle tone and weakness, which, while
typically not progressive, is nonetheless persistent.
In a case report, a 9-year old boy diagnosedwith central core disease
plus mitochrondrial dysfunction (Schreuder et al., 2010) was givenalbuterol for a year. Signiﬁcant progress was seen in activities of daily
living (e.g. self-care, sitting up, raising arms above shoulders, indepen-
dent feeding, improved speech and writing), compared to years prior
to albuterol treatment. Improved FEV and increased muscle strength
were also noted.
An open-label study of 18 patients with central core and multi-
minicore diseases tested albuterol (Messina et al., 2004). Two patients
with central core disease withdrew after 4 months because they did
not note any improvement, while one with minicore disease withdrew
due to increased tremors and palpitations. The remaining 10 subjects
completed the 6 months study without any signiﬁcant adverse effects,
showing signiﬁcant increases in myometry, MRC scores and FVC.
4.3.5. Post-surgical muscle recovery
Twenty otherwise healthy patients requiring medial meniscectomy
were enrolled into a placebo-controlled, double-blind trial, given either
clenbuterol (20 μg b.i.d.) or placebo for 4weeks, followed by a twoweek
wash out period (Maltin et al., 1993). Clenbuterol produced a more
rapid recovery of strength in knee extensor muscles in the operated
leg, and in the non-operated leg strength was increased above baseline
(p = 0.01). The authors concluded that clenbuterol “has therapeutic
potential in the treatment of muscle-wasting conditions”.
4.3.6. Cachectic patients with advanced malignancy
Cachexia (or wasting syndrome) involves a signiﬁcant loss of
weight, muscle atrophy, fatigue, weakness and loss of appetite that
often accompanies late-stage malignancies, as well as AIDS and several
other diseases. Thirteen patients with advanced malignancy and invol-
untaryweight loss were treated with formoterol. Six patients withdrew
before 8 weeks due to the frail, comorbid condition of the patient
population (according to the authors). One withdrew due to
supraventricular tachycardia. Other formoterol side effects were mild
to moderate, transient, and tolerable, involving tremor and peripheral
edema. Of the 7 patients who remained in the study for 8 weeks, 7/8
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and/or function, including an increase in quadriceps volume (p =
0.004) and a trend toward increased quadriceps and grip strength.
5. Summary of pharmacological experience with β2-agonists in
neuromuscular degeneration
Though relatively little attention has been given to a possible thera-
peutic role of β2-agonists for ALS, the cumulative weight of evidence
suggests that this class of pharmaceuticals may beneﬁt a wide range
of neural and/or muscular pathologies characteristic of several other
human neuromuscular diseases. Importantly, each of these diseases
shares important pathologies with ALS. The broad signaling pathways
and pharmacologic responses induced by β2-agonists suggest that the
pathologies of ALS might similarly beneﬁt, despite clear mechanistic
differences in the pathogenesis. The strongest evidence argues that
appropriate dosing of selective β2-agonists should enhance muscle
bulk and muscle strength in ALS patients. While this may have indirect
beneﬁts on degenerating motor nerve terminals (by promoting a
healthier terminal target), there is clear evidence that β2-agonists may
directly protect and restore motor neurons and NMJ in animal models
and human diseases sharing some of the same degenerative changes
as ALS. Finally, β2-agonists suppress pathogenic inﬂammation and in-
duce lipolysis, resulting in greater glucose energymetabolismwhile en-
hancing mitochondrial biogenesis and function. Any one of these
pharmacological effects might be expected to improve the status of
ALS patients, while several of them working synergistically might
constitute a transformative therapy for ALS.
The availability of relatively long-lasting, orally active, safe and selec-
tive β2-agonists, such as clenbuterol and formoterol, makes further tests
and possible treatment for ALS convenient, practical and compelling.
6. Monitoring and managing potential side effects and toxicity.
The majority of the side effects of β2-agonist therapy were mild,
transient and consistent with known adrenergic pharmacology
(below). Unfortunately, the majority of human trials have used non-
speciﬁc β-agonists with a greater spectrum of adverse effects, although
more current animal studies have observed greater efﬁcacy and fewer
side effects using more selective β2-agonists. Additionally, few clinical
studies incorporated a dose titration regimen, which may have allowed
tolerance to β2-adrenoceptor stimulation to develop. This may have sig-
niﬁcantly limited the number and intensity of side effects, as demon-
strated in recent animal studies. Notwithstanding these limitations in
dosing schedules, most clinical studies reported side effects as either
non-existent or mild, transient, and tolerable.
6.1. Minor, common sympathetic-mediated side effects
The most common side effects reported involve sympathetic-like re-
sponses, including: muscle tremors, fasciculations and cramps, tachycar-
dia, palpitations, increased blood pressure, insomnia, excitability,
irritability, nervousness, facial ﬂushing, nausea, headache and sweating.
When these occur, they typically appear quickly, peak within the ﬁrst 3
to 4 days of β2-agonist use and are transient, often dissipating with con-
tinued drug exposure (i.e., ‘tolerate out’) within days of dosing. Impor-
tantly, they are generally dose-related and quickly reversible when
doses are lowered. Except for rare exceptions, these events are described
as mild and tolerable. However, it is important to note between-subject
variability exists. While the majority of studies report no, or mild, tran-
sient, and tolerable adverse events, patients withdrew from the protocol
on rare occasions because of tremors and palpitations. Therefore, careful
monitoring of individual patients for unusual sensitivity seems prudent.
Because the side effects are clearly dose-related, if the patient cannot
tolerate a side effect or wait for the development of tolerance, temporar-
ily lowering the dose should lessen or eliminate the side effect. Onepractical means of reducing the probability of an adverse event is to
employ a dosing protocol starting with relatively low doses and then
increasing the dose over the course of several days to a week or more.
Careful monitoring by a physician familiar with each patient may be
important.
In the event that these side effects persist at doses believed essential
for neuromuscular beneﬁt, then concomitantmedication can be used to
manage each symptom. For example, NSAIDs or acetaminophen can be
used to treat headaches;muscle cramps can often be avoided by staying
well-hydrated or by consuming bananas and oranges. For more serious
cramps, prescription potassiummedicationwith superior bioavailability
is available as a safe and effective option. Over-the-counter taurine
supplementation (at 3–5 g per day) reportedly helps to prevent or
minimize cramping. If insomnia persists, over-the-counter sleep aids
can be tried, and if necessary, a prescription sedative might be helpful
as a temporary solution. Similarly, prescribed medications, accompa-
nied by careful patient monitoring can be considered for treating
nervousness, irritability and nausea.
6.2. Potential cardiovascular toxicity
Some rat studies report cardiac hypertrophy following very high,
chronic doses of β2-agonists (Lynch and Ryall, 2008); (Ryall and
Lynch, 2008). Importantly, the cardiac hypertrophy was transient, in
that a 4-week washout period was sufﬁcient to return the heart back
to baseline sizes. There is also evidence that cardiac hypertrophy can
be minimized or prevented by dose titration and/or employing a drug
holiday (Lynch et al., 1999). By testing a wide range of doses in rats, the
anabolic effects of formoterol on skeletal muscle were found to occur at
far lower doses than those required to induce cardiac hypertrophy
(Ryall et al., 2006), presumably because of that drug's greater selectivity
for β2-adrenoceptors, which comprise about 90% of the β-adrenoceptors
in rat skeletal muscle (Jensen et al., 1995). For treating ALS with selective
β2-agonists this advantage is even greater, because the population of
β-adrenoceptors in human skeletal muscle is nearly exclusively the β2
subtype (Elfellah et al., 1989). Moreover, while the human heart contains
some β2 adrenoceptors (20–40%), the majority are β1 receptors, which
should not be targeted by formoterol (Brodde et al., 2001). Most
importantly, no hint of cardiac hypertrophywas seen in any of the clinical
studies reported, to date.
Tachycardia is one of the ﬁrst indications that β2-agonists are having
a biological effect, and may be used as a surrogate marker for dose
adjustment and the avoidance of cardiotoxicity. One blinded, crossover,
placebo-controlled study tested a wide dose range of oral formoterol
(40 μg to 320 μg) and albuterol (2 to 18 mg) (Lofdahl and Svedmyr,
1989). Heart rate, diastolic blood pressure and skeletal muscle tremor
showed no signiﬁcant changes at lower doses of either drug; the two
drugs showed parallel dose–response effects on all measures with
increasing doses. For the purposes of this discussion, the greatest short-
coming of the data is that only an acute, single dose was tested, with
observations lasting only 8-h. Therefore, the well-established tolerance
to side effects that often occurs after 3 to 4 days ofβ2-agonist dosing had
no chance to occur. No signiﬁcant increases in heart rate were reported
with oral formoterol at or below 180 μg per day for a week, with only a
modest, statistically signiﬁcant increase occurring at 320 μg per day (Lee
et al., 2013). Overall, nearly three dozen published human trials have
tested β2-agonists against a wide variety of neuromuscular maladies
with no problematic cardiovascular effects noted, except for single
patients in each of two studies who displayed a ventricular tachycardia
and an atrialﬂutter, respectively (Greig et al., 2014; Liewluck et al., 2011).
In conclusion, while the apparent cardiovascular risks of chronic,
high-dose systemic β2-agonists are often mentioned in the literature,
the current experience with these compounds in a variety of human
neuromuscular disorders suggests a much lower liability. However, a
single case report of an otherwise healthy 17-year-old body builder in
Eastern Europe may be worth noting as an exception to that point.
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schedule of two days on/two days off), claimed he took no other illicit
drugs or steroids, and suffered a nonfatal coronary infarction
(Kierzkowska et al., 2005). The authors of the case report acknowledged
they had no means of conﬁrming the patient's reported drug use. More
importantly, the clenbuterol dose was approximately 500-times higher
than that administered in the therapeutic clinical studies. Therefore, it
seems possible that more serious cardiovascular effects may occur with
extremely high doses of β-agonists, consistent with the appearance of
cardiac hypertrophy in high dose animal studies. Nonetheless, the doses
recommended for neuromuscular therapy are far below the cardiotoxic
doses. Moreover, possible cardiovascular toxicity may be avoided by
monitoring heart function to assure that tachycardia or hypertension
does not persist. If noted, a judgment weighing the possible risks and
dose de-escalation might be employed, keeping in mind that relatively
mild and transient changes in these cardiovascular parameters often
occur at the onset of dosing or soon after dose escalation. If these events
are relatively mild, time might be allowed for tolerance to develop,
under the close supervision of a physician.
6.3. β-Adrenoceptor desensitization
Continuous activation of β-adrenoceptors results in the gradual
attenuation of the biological response (i.e., tachyphylaxis), a process
precipitated in large part by receptor desensitization. Following
β-adrenoceptor phosphorylation, the receptor is internalized for
dephosphorylation and subsequent recycling to the membrane surface,
or for degradation. In the case of β2-adrenoceptor down-regulation, a
number of possible complications may arise, ranging from the loss or
reduction of β-adrenoceptor mediated effects impairing sympathetic
function, to overcompensation of other systems in response to
decreased sympathetic tone. Anecdotally, body builders have routine-
ly implemented ‘drug holidays’ to avoid a ‘wearing off’ of the anabol-
ic effects of β-agonists. A recent study in rats administered
clenbuterol (Sirvent et al., 2014) observed increased muscle fatigue
over time (an observation occasionally reported by others with
continuous, chronic use), impaired intracellular Ca2+ signaling
and increased calcium-dependent calpain proteolysis. The authors
concluded that chronic clenbuterol treatment might impair calcium
homeostasis that could contribute to remodeling and functional im-
pairment of fast twitch skeletal muscle ﬁbers. These observations
argue for the inclusion of ‘drug holidays’ into chronic dosing sched-
ules and the importance of carefully monitoring patients for changes
in status to differentiate diminished pharmacological response due
to receptor desensitization versus possible disease progression
accompanied by loss of function.
Another potential concern is that once the β-adrenoceptor system
has achieved a highly desensitized state, secondary problems such as a
rapid ‘rebound response’ could occur following abrupt discontinuation
of β-agonist administration. Addressing this issue requires careful
selection of the dose and dosing schedule, along with regular and
thorough patient monitoring. This poses the question, ‘What dosing
schedule might be applied to mitigate problems associated with
β2-adrenoceptor desensitization?’ It is generally acknowledged that
minimizing receptor desensitization requires a dosing schedule that
alternates periods of drug administration with ‘drug holidays’. Because
the optimal dosing schedule will vary depending on the speciﬁc
β-agonist, its dose level and the individual, whatever dosing regimen
is selected must be complemented with careful observation of the
patient and possible modiﬁcations to dose in an attempt to assure
that desensitization has not occurred. If desensitization is strongly
suspected, changes to the dosing regimen should be considered, ranging
from increasing the dose (assuming intolerable side effects are not
induced) to inserting an extra one-to-two week drug holiday, after
which dosing is resumed while careful monitoring by a physician
continues.6.4. Drug interactions
In addition to the possible side effects resulting from β2-
adrenoceptor stimulation, there exists the possibility of unwanted side
effects arising from interactions with other drugs taken by ALS patients.
While few studies in the literature warn of serious drug–drug interac-
tions with β-agonists, it is always wise for the prescribing physician
to monitor and manage possible interactions. It has been noted that
β-agonists may potentiate the effects of theophylline and anti-
cholinergics, while an increased risk of arrhythmias may occur with
concomitant administration of β-agonists and MAO-inhibitors or tricy-
clic antidepressants. Caution and careful, regular monitoring should be
employed in these cases, as well as with those patients with underlying
cardiopathologies and/or the use of β-agonists or β-antagonists for
other medical reasons. Risks of complications from possible drug inter-
actions need to be weighed against the intended beneﬁts of treating a
progressive, life-threatening disease for which there currently is no
adequate therapy.
7. Discussion and conclusions
This review explores the hypothesis that stimulation of β2-
adrenoceptors may constitute a novel, safe and effective therapy for
ALS. Research in animalmodels has established that β-agonists can pro-
vide a wide variety of beneﬁcial pharmacological effects, mediated via
the plethora of signaling pathways and transcription factors that alter
the structure and function of skeletal muscle, neurons, glia and
immunocytes in ways that could improve the status of ALS patients.
Moreover, over 30 clinical studies, several of which were double-blind
and placebo-controlled, tested β-agonists in different neuromuscular
diseases that share one or more pathologies with ALS. While the ALS
community has so far largely ignored β-agonists as potential therapies,
the ‘weight of evidence’ from studies involving other neuromuscular
disorders provides intriguing, albeit preliminary evidence that β2-
agonists may correct many of the serious neural andmuscular deﬁcien-
cies also seen in ALS. The possibly of synergistic interactions between
the multiple pathways induced by β2-agonists provides even more
compelling support for the hypothesis.
The fact that several long-lasting, orally active and selective β2-
agonists have been approved and used safely in humans for decades
provides a convenient, practical and compelling means for more direct
and deﬁnitive testing of this hypothesis. Positive results obtained in
ALS patients tested in appropriately controlled and sufﬁciently powered
clinical trials could quickly lead to ‘repositioning’ or ‘repurposing’ oral
β2-agonists for treatment of ALS. This circumstance conceivably creates
an unprecedented opportunity for rapidly transforming the treatment
of this serious, unmet medical need.
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